our Premium Content: News alerts, weekly reports and conference planners
DRUG:
anti-CD30 CAR T cells
i
Other names: anti-CD30 CAR T cells, CD30-targeted chimeric antigen receptor T cell therapy, CD30-Targeted Genetically-modified Autologous T-cell immunotherapy Injection
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Our work demonstrates the combined administration of ASCT and CAR30 T-cell therapy is well-tolerate and highly effective in r/r cHL and ALCL, even in PET-positive or chemorefractory patients who are expected to have inferior outcome after ASCT, although further large-scaled validation in prospective clinical trial is warranted. Trial registration The trial was registered with the Chinese Clinical Trial Registry (ChiCTR, number ChiCTR2100053662).